CRBPHIGH SIGNALRISK10-K

CRBP underwent a significant pipeline restructuring, replacing CRB-601 with expanded focus on CRB-701 and CRB-913, while experiencing substantially deteriorating financial performance across key metrics.

The company appears to have made strategic decisions to discontinue or deprioritize CRB-601 (anti-integrin monoclonal antibody) in favor of concentrating resources on their ADC and obesity programs. This pipeline pivot, combined with meaningfully higher operating losses and cash burn, suggests CRBP is in a critical period requiring careful monitoring of cash runway and clinical progress.

Comparing 2026-03-09 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

While revenue grew notably during the period, the company's operational performance deteriorated substantially with operating losses expanding significantly and cash burn accelerating meaningfully. The balance sheet shows mixed signals - cash and equivalents increased notably to $28.5M (likely from financing activities), but current liabilities also grew substantially, indicating higher near-term obligations. Despite the improved cash position, the acceleration in operating cash outflows raises questions about funding runway given the company's clinical-stage nature.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+97.6%
$2.4M→$4.8M

Strong top-line growth of 97.6% — accelerating demand or successful expansion into new markets.

Net Income
P&L
-95.3%
-$40.2M→-$78.5M

Net income declined 95.3% — review whether driven by operations, interest costs, or non-recurring items.

Interest Expense
P&L
-89.8%
$24K→$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Income
P&L
-75.1%
-$48.7M→-$85.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+75.1%
$11.8M→$20.7M

Current liabilities surged 75.1% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
+65.7%
$17.2M→$28.5M

Cash position surged 65.7% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
-54.3%
-$41.8M→-$64.5M

Operating cash flow fell 54.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Liabilities
Balance Sheet
+53.8%
$13.5M→$20.7M

Liabilities grew 53.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
-17.1%
$21.6M→$17.9M

Debt reduced 17.1% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-11
ADDED
Management s Discussion and Analysis of Financial Condition and Results of Operations 56 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 64 9A.
These factors include, but are not limited to: our history of operating losses; our current and future capital requirements and our ability to satisfy our capital needs; our ability to complete required clinical trials of our product candidates and obtain approval from the U.S.
(the Company or Corbus ) is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.
Corbus pipeline includes CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE") and CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity.
and Europe (the "Western study") enrolling patients with advanced solid tumors associated with Nectin-4 expression.
In June 2025, the Company began dosing participants in the PD-1 combination arm with CRB-701 in combination with Keytruda (pembrolizumab).
The Company has received fast track designation for CRB-701 from the U.S.
Food and Drug Administration (the "FDA") for the treatment of relapsed or refractory metastatic cervical cancer in December 2024 and in recurrent or metastatic head and neck squamous cell carcinoma ( HNSCC ) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025.
CRB-701 is currently being investigated by CSPC in a Phase 3 clinical trial in patients with cervical cancer in China (the "China study").
REMOVED
Management s Discussion and Analysis of Financial Condition and Results of Operations 55 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 63 9A.
(the Company or Corbus ) is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.
Corbus oncology pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE") and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity.
CRB-701 is currently being investigated by CSPC in a Phase 1 dose expansion clinical trial in patients with advanced solid tumors in China (the "China study").
The Company commenced a corresponding Phase 1 dose escalation study in the U.S.
(the "Western study") in April 2024 and completed enrollment of the dose escalation phase in October 2024.
The dose optimization portion of the Western study is currently ongoing and the Company is in the process of adding additional clinical sites in Europe.
Figure 1: CRB-701 Next Generation Nectin-4 Targeting ADC On June 1, 2024, CSPC presented updated Phase 1 dose escalation clinical data at the American Society of Clinical Oncology ( ASCO ) Annual General Conference building upon the data presented at ASCO Genitourinary Cancers Symposium ( ASCO GU ) on January 26, 2024.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →